BioXcel Therapeutics Inc BTAI

NAS: BTAI | ISIN: US09075P1057   14/11/2024
0,520 USD (-15,99%)
(-15,99%)   14/11/2024
Grafiek BioXcel Therapeutics Inc Grafiek BioXcel Therapeutics Inc

BioXcel Therapeutics Inc in het nieuws

2 december 2023 · Moore Kuehn, PLLC Encourages BioXcel Therapeutics, Inc. Investors to Contact Law Firm · Persbericht

26 oktober 2023 · Thinking about buying stock in Vista Energy, Ault Alliance, ATAI Life Sciences, LianBio, or BioXcel Therapeutics? · Persbericht

10 oktober 2023 · Thinking about buying stock in Immunic, BioXcel Therapeutics, Coherent Corp, Emx Royalty, or Lexicon Pharmaceuticals? · Persbericht

5 oktober 2023 · Thinking about buying stock in Vivos Therapeutics, Twin Ridge Capital Acquisition, BioXcel Therapeutics, Cocrystal Pharma, or Cambium Networks? · Persbericht

3 september 2023 · Important September 5, 2023 Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds BioXcel Therapeutics, Inc. Investors of Securities Fraud Class Action Lawsuit · Persbericht

26 augustus 2023 · BTAI CLASS ACTION NOTICE: Kessler Topaz Meltzer & Check, LLP Reminds BioXcel Therapeutics, Inc. (BTAI) Shareholders of Securities Fraud Class Action Lawsuit and Encourages Investors with Substantial Losses to Contact the Firm · Persbericht

25 augustus 2023 · BTAI Investors Have Opportunity to Lead BioXcel Therapeutics, Inc. Securities Fraud Lawsuit · Persbericht

19 augustus 2023 · BIOXCEL SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In BioXcel To Contact Him Directly To Discuss Their Options · Persbericht

19 augustus 2023 · BIOXCEL SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against BioXcel Therapeutics, Inc. - BTAI · Persbericht

17 augustus 2023 · Securities Class Action Reminder for (BTAI) Investors: Kessler Topaz Meltzer & Check, LLP Reminds BioXcel Therapeutics, Inc. Investors of Upcoming Deadline in Securities Fraud Class Action Lawsuit · Persbericht

Profiel BioXcel Therapeutics Inc

Biotechnologie
Fabricage van farmaceutische preparaten
Gezondheidstechnologie
Productie

Website: www.bioxceltherapeutics.com

Hoofdzetel: New Haven, Connecticut vlag Verenigde Staten

CEO: Vimal Mehta

Werknemers: 173

Mijn selecties